Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis - European Journal of Cancer

the ONA take:

A systematic review of prospective randomized controlled trials was conducted to compare cardiotoxicity of anthracyclines in patients with breast cancer. Anthracyclines play a broad and important role in operable or metastatic breast cancer; however, cardiotoxicity can lead to potentially clinically meaningful treatment delays or discontinuations.

In this study, MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and Google Scholar were searched for prospective randomized controlled trials comparing nonanthracycline based regimens (NON), doxorubicin (DOX), epirubicin (EPI), and liposomal doxorubicin (LD). Primary outcome measure was cardiac events grade 3 or greater (CE3) based on Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. The search produced 19 trials that met eligibility criteria and were included in this Bayesian network meta-analysis.

Study findings indicate that CE3 rates were higher with DOX than with NON. LD statistically trended to lower cardiac event rates than DOX and appears to be the least cardiotoxic. Overall, incidence of CE3 with any type of anthracycline was low, and these drugs can be safely administered if cumulative dose limits are not exceeded.

Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in br
Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in br
READ FULL ARTICLE From www.ejcancer.com
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs